Silence Therapeutics (LON:SLN) issued its quarterly earnings data on Tuesday. The company reported GBX (12.40) (($0.16)) EPS for the quarter, Bloomberg Earnings reports. Silence Therapeutics had a negative return on equity of 21.42% and a negative net margin of 34,475.00%.

LON SLN traded up GBX 0.50 ($0.01) on Thursday, hitting GBX 144.50 ($1.88). 400 shares of the company traded hands, compared to its average volume of 13,380. Silence Therapeutics has a 52-week low of GBX 71.88 ($0.94) and a 52-week high of GBX 254.75 ($3.32).

Separately, Peel Hunt reiterated a “buy” rating on shares of Silence Therapeutics in a research report on Tuesday.

About Silence Therapeutics

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.